These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 6443368)

  • 21. Relative abuse liability of triazolam: experimental assessment in animals and humans.
    Griffiths RR; Lamb RJ; Ator NA; Roache JD; Brady JV
    Neurosci Biobehav Rev; 1985; 9(1):133-51. PubMed ID: 2858078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of mazindol for abuse liability.
    Pickworth WB; Klein SA; Bunker EB; Henningfield JE
    NIDA Res Monogr; 1990; 105():443. PubMed ID: 1876067
    [No Abstract]   [Full Text] [Related]  

  • 23. Cognitive impairments induced by triazolam in healthy volunteers: antagonism by a partial inverse agonist of benzodiazepine receptor.
    Warot D; Danjou P; Douillet P; Keane P; Puech AJ
    Therapie; 1994; 49(1):23-6. PubMed ID: 8091361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discriminative stimulus effects of zolpidem in pentobarbital-trained subjects: I. Comparison with triazolam in rhesus monkeys and rats.
    Rowlett JK; Woolverton WL
    J Pharmacol Exp Ther; 1997 Jan; 280(1):162-73. PubMed ID: 8996194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of triazolam (TZ) on matching-to-sample (MTS) performance in humans.
    Roache JD; Cherek DR; Cowan KA; Spiga R; Bennett RH; Grabowski J
    NIDA Res Monogr; 1989; 95():475-6. PubMed ID: 2641037
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences.
    Greenblatt DJ; Harmatz JS; von Moltke LL; Wright CE; Durol AL; Harrel-Joseph LM; Shader RI
    J Pharmacol Exp Ther; 2000 May; 293(2):435-43. PubMed ID: 10773013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alprazolam absorption kinetics affects abuse liability.
    Mumford GK; Evans SM; Fleishaker JC; Griffiths RR
    Clin Pharmacol Ther; 1995 Mar; 57(3):356-65. PubMed ID: 7697954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of repeated acquisition methodologies: implications for the detection of drug-induced disruption in human learning.
    Bickel WK; Higgins ST; Hughes JR
    NIDA Res Monogr; 1990; 100():99-111. PubMed ID: 2132780
    [No Abstract]   [Full Text] [Related]  

  • 29. Discriminative stimulus effects of benzodiazepine agonists and partial agonists in pentobarbital-trained rhesus monkeys.
    Rowlett JK; Woolverton WL
    Behav Pharmacol; 1998 Mar; 9(2):81-92. PubMed ID: 10065928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional antagonism of the caffeine-discriminative stimulus by triazolam in humans.
    Oliveto AH; Bickel WK; Hughes JR; Higgins ST; Badger G
    Behav Pharmacol; 1997 Jun; 8(2-3):124-38. PubMed ID: 9833008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. L-Dopa-induced sedation: a double-blind cross-over controlled study versus triazolam and placebo in healthy volunteers.
    Andreu N; Chalé JJ; Senard JM; Thalamas C; Montastruc JL; Rascol O
    Clin Neuropharmacol; 1999; 22(1):15-23. PubMed ID: 10047929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human multioperant responding: effects of triazolam.
    Spiga R; Cherek DR; Meisch RA; Roache JD
    NIDA Res Monogr; 1989; 95():477-8. PubMed ID: 2641038
    [No Abstract]   [Full Text] [Related]  

  • 33. Human drug self-administration: double-blind comparison of pentobarbital, diazepam, chlorpromazine and placebo.
    Griffiths RR; Bigelow G; Liebson I
    J Pharmacol Exp Ther; 1979 Aug; 210(2):301-10. PubMed ID: 458637
    [No Abstract]   [Full Text] [Related]  

  • 34. Discriminative-stimulus effects of triazolam in light and moderate drinkers.
    Rush CR; Kelly TH; Fillmore MT; Hays LR
    Alcohol Clin Exp Res; 2003 Apr; 27(4):638-46. PubMed ID: 12711926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repeated administration of diazepam and triazolam to subjects with histories of drug abuse.
    Roache JD; Griffiths RR
    Drug Alcohol Depend; 1986 May; 17(1):15-29. PubMed ID: 3720528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycodan) in non-drug-abusing volunteers.
    Zacny JP
    Psychopharmacology (Berl); 2003 Jan; 165(2):146-56. PubMed ID: 12404072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Profiling the subjective, psychomotor, and physiological effects of a hydrocodone/acetaminophen product in recreational drug users.
    Zacny JP; Gutierrez S; Bolbolan SA
    Drug Alcohol Depend; 2005 Jun; 78(3):243-52. PubMed ID: 15893155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute tolerance to triazolam during continuous and step infusions: estimation of the effect offset rate constant.
    Kroboth PD; Bertz RJ; Smith RB
    J Pharmacol Exp Ther; 1993 Mar; 264(3):1047-55. PubMed ID: 8450449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug preference in humans: double-blind choice comparison of pentobarbital, diazepam and placebo.
    Griffiths RR; Bigelow GE; Liebson I; Kaliszak JE
    J Pharmacol Exp Ther; 1980 Dec; 215(3):649-61. PubMed ID: 7441524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the behavioral effects of bretazenil and flumazenil in triazolam-dependent and non-dependent baboons.
    Weerts EM; Ator NA; Kaminski BJ; Griffiths RR
    Eur J Pharmacol; 2005 Sep; 519(1-2):103-13. PubMed ID: 16129429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.